INDOMETHACIN CAPSULE

Quick Detail

Package & Delivery Lead Time

Detailed Description

Product No：AMC11007-01 Specification：25mg, 10*10/box Category：Antibiotics Properties：Capsule Criteria：BP,USP Place Of Origin ： China (Mainland) Brand Name：Medipharm Validity：Three Years Main Composition： Each capsule contains indomethacin 25mg. Appearance：White、Almost White Granular Material Or Powder。 Indications: Carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals Indomethacin capsules have been found effective in active stages of the following: 1.Moderate to severe rheumatoid arthritis including acute flares of chronic disease. 2.Moderate to severe ankylosing spondylitis. 3.Moderate to severe osteoarthritis. 4.Acute painful shoulder (bursitis and/or tendinitis). 5.Acute gouty arthritis. Dasage：Carefully consider the potential benefits and risks of indomethacin and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. After observing the response to initial therapy with indomethacin, the dose and frequency should be adjusted to suit an individual patient's needs.Indomethacin is available as 25 mg and 50 mg capsules.Adverse reactions appear to correlate with the size of the dose of indomethacin in most patients but not all. Therefore, every effort should be made to determine the smallest effective dosage for the individual patient.Pediatric UseIndomethacin ordinarily should not be prescribed for pediatric patients 14 years of age and under Adult Use Dosage Recommendations for Active Stages of the Following: Moderate to severe rheumatoid arthritis including acute flares of chronic disease; moderate to severe ankylosing spondylitis; and moderate to severe osteoarthritis. Suggested Dosage: Indomethacin capsules 25 mg b.i.d. or t.i.d. If this is well tolerated, increase the daily dosage by 25 mg or by 50 mg, if required by continuing symptoms, at weekly intervals until a satisfactory response is obtained or until a total daily dose of 150 mg to 200 mg is reached. Doses above this amount generally do not increase the effectiveness of the drug. In patients who have persistent night pain and/or morning stiffness, the giving of a large portion, up to a maximum of 100 mg, of the total daily dose at bedtime may be helpful in affording relief. The total daily dose should not exceed 200 mg. In acute flares of chronic rheumatoid arthritis, it may be necessary to increase the dosage by 25 mg or, if required, by 50 mg daily. If minor adverse effects develop as the dosage is increased, reduce the dosage rapidly to a tolerated dose and observe the patient closely.If severe adverse reactions occur, stop the drug. After the acute phase of the disease is under control, an attempt to reduce the daily dose should be made repeatedly until the patient is receiving the smallest effective dose or the drug is discontinued.Careful instructions to, and observations of, the individual patient are essential to the prevention of serious, irreversible, including fatal, adverse reactions. As advancing years appear to increase the possibility of adverse reactions, indomethacin should be used with greater care in the elderly. Acute painful shoulder (bursitis and/or tendinitis). Initial Dose: 75 mg to 150 mg daily in 3 or 4 divided doses. The drug should be discontinued after the signs and symptoms of inflammation have been controlled for several days. The usual course of therapy is 7 to 14 days. Acute gouty arthritis.Suggested Dosage: Indomethacin capsules 50 mg t.i.d. until pain is tolerable. The dose should then be rapidly reduced to complete cessation of the drug. Definite relief of pain has been reported within 2 to 4 hours. Tenderness and heat usually subside in 24 to 36 hours, and swelling gradually disappears in 3 to 5 days. Indomethacin is contraindicated in patients with known hypersensitivity to indomethacin or the excipients .Indomethacin should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic/anaphylactoid reactions to NSAIDs have been reported in such patients. Indomethacin is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery. Contra-Indications：Indomethacin is contraindicated in patients with known hypersensitivity to indomethacin or the excipients .Indomethacin should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic/anaphylactoid reactions to NSAIDs have been reported in such patients.Indomethacin is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery. Adverse Reaction ：The adverse reactions for indomethacin capsules listed in the following table have been arranged into two groups: incidence greater than 1%; and incidence less than 1%. The incidence for group was obtained from 33 double-blind controlled clinical trials reported in the literature (1,092 patients). The incidence for group was based on reports in clinical trials, in the literature, and on voluntary reports since marketing. The probability of a causal relationship exists between indomethacin and these adverse reactions, some of which have been reported only rarely.Causal Relationship UnknownOther reactions have been reported but occurred under circumstances where a causal relationship could not be established. However, in these rarely reported events, the possibility cannot be excluded. Therefore, these observations are being listed to serve as alerting information to physicians: Cardiovascular: thrombophlebitis,Hematologic: Although there have been several reports of leukemia, the supporting information is weak.Genitourinary: urinary frequency A rare occurrence of fulminant necrotizing fasciitis, particularly in association with Group A β-hemolytic streptococcus, has been described in persons treated with non-steroidal anti-inflammatory agents, including indomethacin, sometimes with fatal outcome . Packing： Inner Packing ： Yellow-White Capsule，Blister Packaging Outer Packing ：10x10/Box, 200Boxes/Carton Carton Size：67*47*33.5cm3(Only For Reference) Other Options： Style；25mg,1000's/jar

Basic Company Information

Anhui Medipharm Co.,Ltd.

Company Advantage

Detail Company Introduction

Trade Information